Mitsubishi Tanabe Pharma America
Peter Werner has a diverse work experience in the pharmaceutical and medical fields. Peter is currently serving as the Medical Science Director at Mitsubishi Tanabe Pharma America since 2020. Prior to this, Peter founded their own consulting and coaching services business in 2016. Peter provided life and executive coaching to highly skilled professionals and consulting services to businesses in the pharmaceutical and biotech industries. Peter also worked as a Consultant at Medday Pharmaceuticals from 2019 to 2020 where they supported medical and clinical affairs for a candidate drug.
Before starting their consultancy, Peter held positions at Sunovion Pharmaceuticals Inc. as Associate Director, Medical Affairs from 2011 to 2016. At Forest Laboratories, they served as Assistant Director, Medical Affairs from 2009 to 2011 and as a Senior Therapeutic Specialist from 2006 to 2009. Peter also held academic positions at Albert Einstein College of Medicine as an Associate Professor, Neurology and Pathology from 1998 to 2006, and at Mount Sinai School of Medicine as an Assistant Professor in 1997. Throughout their career, Peter has demonstrated expertise in research, clinical trials, publication strategy, and providing medical and scientific guidance.
Peter Werner attended the Icahn School of Medicine at Mount Sinai from 1991 to 1995. Their degree and field of study during this period are unspecified. Additionally, they also have a history with the University of Tübingen, although the specific years of enrollment and details of their degree and field of study at this institution are unknown.
Mitsubishi Tanabe Pharma America
We are taking on the challenges of complex and debilitating conditions and are committed to meeting the needs of people suffering from serious and often life-threatening illnesses. Today, we are focused on driving scientific discovery in many areas. Our focus remains on bringing treatment to people living with ALS as we strive to make a meaningful difference in their lives. Many people living with amyotrophic lateral sclerosis (ALS) have unmet medical needs. We are committed to doing our best to find solutions that may help address those needs. We continue to expand our work to deepen our understanding of ALS, explore potential biomarkers to aid in further research and seek new answers. Every day we tackle tough challenges in science and medicine. Our teams work diligently to develop smart options that will enable healthcare providers to offer safe and effective treatments for devastating illnesses. Please see our LinkedIn community guidelines here: http://www.mt-pharma-america.com/pdf/LinkedIn-Community-Guidelines.pdf